openPR Logo
Press release

Benign Prostatic Hyperplasia Therapeutics Market - combination drug therapy segment is anticipated to record a high CAGR during the forecast period

04-17-2019 10:26 AM CET | Health & Medicine

Press release from: Allied Market Research

Benign Prostatic Hyperplasia Therapeutics Market

Benign Prostatic Hyperplasia Therapeutics Market

Benign Prostatic Hyperplasia Therapeutics Market is projected to reach $20,097 million in 2025, registering a CAGR of 8.1% from 2018 to 2025.

Benign prostatic hyperplasia (BPH) is a medical condition in which a male’s prostate gland size increases abnormally. This condition results in problems to start urination, weak urine stream, inability to empty the urinary bladder, and enhanced urine frequency usually at night. BPH therapeutics are drugs categorized into three different classes namely, alpha blocker, 5-alpha reductase inhibitor, and phosphodiesterase-5 inhibitor.

These drugs relax the smooth bladder muscles or shrink the abnormal prostate growth to alleviate the BHP symptoms. The relaxation of the muscles of the bladder loosens the prostates grip on the urethra facilitating urine to flow more freely. Whereas, the shrinkage of the size of the prostate reduces the pressure exerted by the prostate on the urethra, resulting in free flow of urine.

Increasing prevalence of benign prostatic hyperplasia, rising global geriatric population, and soaring awareness related to urological disorders and prostate cancer across the world are the factors that drive the global benign prostatic hyperplasia therapeutics market growth. However, higher adoption rate of minimally-invasive surgical therapies instead of BPH therapeutics is expected to impede the market growth. Conversely, high market potential in the untapped emerging economies and presence of several pipeline products are expected to provide many opportunities during the forecast period.

Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/4708

The utilization rate of alpha blockers is high, owing to high availability of these products characterized by a higher success rate and lesser side effects. However, the 5-alpha reductase inhibitor segment is expected to grow at a high CAGR during the forecast period.

The mono drug therapy segment is the largest segment in the global benign prostatic hyperplasia therapeutics market, expanding at a moderate CAGR during the forecast period. On the other hand, the combination drug therapy segment is anticipated to record a high CAGR during the forecast period.

Make an Enquiry before Buy @ https://www.alliedmarketresearch.com/purchase-enquiry/4708

Key findings of the Benign Prostatic Hyperplasia Therapeutics Market:
• The phosphodiesterase-5 inhibitor segment accounted for nearly one-sixth share of the global benign prostatic hyperplasia therapeutics market in 2017.
• The mono drug therapy segment is expected to grow at a CAGR of 7.6% from 2018 to 2025.
• Europe accounted for around one-third share of the global market in 2017.
• LAMEA is expected to provide lucrative market growth opportunities and grow at a CAGR of 9.6% from 2018 to 2025.

North America was the leading revenue contributor to the global benign prostatic hyperplasia therapeutics market in 2017, and is expected to dominate the market during the forecast period. This is attributed to the early approval of BPH drugs and high adoption of drugs in this region. However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period, owing to increase in affordability, surge in healthcare expenditure, and rise in awareness towards safe BPH drugs.

Access Full Summery @ https://www.alliedmarketresearch.com/benign-prostatic-hyperplasia-therapeutics-market

About Us:

Allied Market Research, a market research and advisory company of Allied Analytics LLP, provides business insights and market research reports to large as well as small & medium enterprises. The company assists its clients to strategize business policies and achieve sustainable growth in their respective market domain.

Contact:

David Correa

5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States

Toll Free (USA/Canada):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1⟨855⟩550-5975

help@alliedmarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Benign Prostatic Hyperplasia Therapeutics Market - combination drug therapy segment is anticipated to record a high CAGR during the forecast period here

News-ID: 1706667 • Views: 129

More Releases from Allied Market Research

Epinephrine Autoinjector Market to Boost Revenue with Massive Growth
Global Epinephrine Autoinjector Market report it provides a vital recent industry data which covers in general market situation along with future scenario for industry around the Globe. It also consists of major data along with forecasts of a global market along with clear presentation of diagrams (charts and tables). According to a new report published by Allied Market Research, titled, “Epinephrine Autoinjector Market by Dosage (0.15mg, 0.3mg, and 0.5mg Dosage); Age
Enterprise Medical Image Viewers Market Challenges and New Trends
Global Enterprise Medical Image Viewers Market report it provides a vital recent industry data which covers in general market situation along with future scenario for industry around the Globe. It also consists of major data along with forecasts of a global market along with clear presentation of diagrams (charts and tables). According to a new report published by Allied Market Research, titled, “Enterprise Medical Image Viewers Market by Type (Devices and
Prenatal Vitamin Supplements Market Analysis of The Current and Emerging Trends
Global Prenatal Vitamin Supplements Market report it provides a vital recent industry data which covers in general market situation along with future scenario for industry around the Globe. It also consists of major data along with forecasts of a global market along with clear presentation of diagrams (charts and tables). According to a new report published by Allied Market Research, titled, “Prenatal Vitamin Supplements Market by Dosage Forms (Capsule, Powder and
Multiple Myeloma Market Analysis of Top industry Scenario
Global Multiple Myeloma Market report it provides a vital recent industry data which covers in general market situation along with future scenario for industry around the Globe. It also consists of major data along with forecasts of a global market along with clear presentation of diagrams (charts and tables). According to a new report published by Allied Market Research, titled, “Multiple Myeloma Market by Therapeutics Type [Chemotherapy and Other Drugs (Traditional

All 5 Releases


More Releases for Benign

Global Benign Prostatic Hyperplasia Treatment Devices Market Outlook 2018-2025 K …
A detailed market study on "Global Benign Prostatic Hyperplasia (BPH) Treatment Devices Market" examines the performance of the Benign Prostatic Hyperplasia (BPH) Treatment Devices market. It encloses an in-depth Research of the Benign Prostatic Hyperplasia (BPH) Treatment Devices market state and the competitive landscape globally. This report analyzes the potential of Benign Prostatic Hyperplasia (BPH) Treatment Devices market in the present and the future prospects from various angles in detail. The
Benign Positional Vertigo Market by Type - Benign, Paroxysmal, Positional and Ve …
The Global Benign Positional Vertigo Market is growing at the CAGR of ~4.0% during the forecast period and expected to reach US$ 797.3 million by 2023. Benign Positional Vertigo Market Segments: Worldwide Benign Positional Vertigo Market has been segmented on the basis of type which Benign, Paroxysmal, Positional, Vertigo, and others. On the basis of diagnosis, it is segmented into Electroencephalogram (EEG), Electronystagmography (ENG), Head CT, Head MRI, Hearing test, Magnetic resonance
Cold Plasma Market Benign Rate by 2025
Global Cold Plasma Market: Snapshot Cold plasma, additionally called non-warm plasma or non-balance plasma, is a sort of plasma—ordinarily known as the fourth condition of issue—which has gas particles show at direct temperature and electrons at moderately high temperatures. The properties of plasma have been widely looked into in the course of recent decades and an extensive number of front line utilizations of cold plasma innovation has exuded. Cold plasma isn't in
Benign Prostatic Hyperplasia Therapeutics Market Epidemiology Analysis, Therapy, …
The global benign prostatic hyperplasia therapeutics market is expected to witness significant growth, as increased number of effective treatments are available for cancer. Increasing awareness regarding various cancer treatment drugs, technological advancements, and growing demand for safe and effective medications are acting as the major growth drivers for the benign prostatic hyperplasia therapeutics market. Globally, regulatory bodies are adding to the growth of the market with provision of funding, grants
Benign Prostatic Hyperplasia and Prostatitis Devicebased Treatments Market
ReportsWorldwide has announced the addition of a new report title Benign Prostatic Hyperplasia and Prostatitis Devicebased Treatments Market to its growing collection of premium market research reports. This analysis includes a discussion of products, competitors, market forecasts, and opportunities in the global market for BPH and prostatitis treatment devices. Topics Covered Include: An overview of device-based and pharmacological therapies for BPH and prostatitis. Global and country/region-specific market forecasts, including forecasts by product segment. Competitive analyses
Benign Prostatic Hyperplasia Therapeutics Development Pipeline Overview for H1 2 …
2017 Benign Prostatic Hyperplasia pipeline market report of on global industry analysis and opportunity assessment H1 report provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Get Discount on this Research Report at http://www.reportsnreports.com/contacts/discount.aspx?name=1010746 Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a